Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia

Phase 2 Completed 120 enrolled Medical Research Council

Open-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have Burkitt's lymphoma or Burkitt's leukemia.

Timeline

Start: 2008-11
Primary completion: —
Completion: 2008-12

Publications

Results Mead GM, Barrans SL, Qian W, Walewski J, Radford JA, Wolf M, Clawson SM, Stenning SP, Yule CL, Jack AS; UK National Cancer Research Institute Lymphoma Clinical Studies Group; Australasian Leukaemia and Lymphoma Group. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008 Sep 15;112(6):2248-60. doi: 10.1182/blood-2008-03-145128. Epub 2008 Jul 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	—	Intravenous
Subject	Cytarabine	Small molecule	—	Intrathecal
Subject	Doxorubicin	Other / unclassified	—	Intravenous
Subject	Etoposide	Small molecule	—	Intravenous
Subject	Ifosfamide	Small molecule	—	Intravenous
Subject	Methotrexate	Small molecule	3000 mg/m2	Intravenous
Subject	Vincristine	Small molecule	—	Intravenous
Background	Leucovorin	Small molecule	—	Intravenous
Background	filgrastim	Protein / enzyme biologic	—	Subcutaneous

Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia

Summary

Timeline

Publications

Drugs

Indications